STOCK TITAN

SR One funds disclose 6.4% Veradermics (MANE) stake after IPO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

SR One Capital–affiliated funds filed a Schedule 13D disclosing a 6.4% stake in Veradermics, Inc. common stock. The funds collectively own 2,401,868 shares of Veradermics’ Common Stock following the company’s initial public offering of 17,339,294 shares at $17.00 per share.

SR One Fund II Aggregator holds 1,621,121 shares and AMZL holds 780,747 shares, largely from the automatic conversion of Series C preferred stock at a 10.067‑for‑1 ratio plus IPO purchases. The filing states the shares were acquired for investment purposes, using fund working capital without borrowing, and outlines registration rights and a 180‑day IPO lock‑up restricting sales and hedging transactions.

Positive

  • None.

Negative

  • None.

Insights

SR One funds report a 6.4% investment stake in Veradermics following its IPO, with standard lock-up and registration rights.

SR One Fund II Aggregator and AMZL together hold 2,401,868 Veradermics common shares, equal to 6.4% of the company’s February 5, 2026 outstanding shares. Holdings came from converted Series C preferred stock plus 450,000 IPO shares at $17.00 per share.

The filing describes these positions as acquired for investment purposes, with no specific plans for corporate actions or governance changes. Standard investors’ rights and piggyback registration rights could later facilitate share resales once the 180-day IPO lock-up period and any registration conditions are satisfied.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


SR One Capital Management, LLC
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney in fact for Simeon George, M.D., Managing Member
Date:02/11/2026
SR One Capital Fund II Aggregator, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:02/11/2026
SR One Capital Partners II, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:02/11/2026
AMZL, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:02/11/2026
SR One Capital SMA Partners, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:02/11/2026
Simeon George
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D.
Date:02/11/2026
Comments accompanying signature:
This Statement was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

FAQ

How much of Veradermics (MANE) do the SR One funds beneficially own?

The SR One funds collectively beneficially own 2,401,868 shares of Veradermics common stock, representing 6.4% of the outstanding shares as of February 5, 2026. This ownership combines positions held by SR One Fund II Aggregator and AMZL.

How did SR One Fund II Aggregator acquire its Veradermics (MANE) shares?

SR One Fund II Aggregator bought 450,000 IPO shares at $17.00 per share and previously purchased Series C preferred stock that converted into 1,171,121 common shares at a 10.067‑for‑1 ratio, resulting in 1,621,121 common shares held.

What are AMZL’s holdings in Veradermics (MANE)?

AMZL purchased 7,859,781 Series C preferred shares that automatically converted into 780,747 Veradermics common shares at a 10.067‑for‑1 ratio. These 780,747 shares equal 2.1% of Veradermics’ common stock outstanding as of February 5, 2026.

Did SR One or its funds borrow money to buy Veradermics (MANE) shares?

The filing states that working capital of each fund financed the Veradermics share purchases. It specifies that no part of the purchase price for either SR One Fund II Aggregator’s or AMZL’s shares was represented by borrowed funds or similar financing.

What lock-up restrictions apply to the SR One funds’ Veradermics (MANE) shares?

Each fund signed a 180‑day lock-up from February 3, 2026, agreeing not to sell, hedge, pledge, or demand registration of Veradermics common stock without underwriter consent. This restricts transfers, short sales, and certain registration actions during that period.

What registration rights do the SR One funds have for Veradermics (MANE) shares?

Under a Third Amended and Restated Investors’ Rights Agreement, the funds hold demand and piggyback registration rights. They can request S‑1 or S‑3 registrations above set dollar thresholds and include their shares in certain company-initiated offerings, subject to customary limitations and expense allocations.

Does the SR One group plan to change control or management at Veradermics (MANE)?

The filing states the shares were acquired for investment purposes and that the reporting persons have no present plans for mergers, asset sales, management changes, capital structure changes, or other control-related corporate actions beyond the general possibility of buying or selling shares.
VERADERMICS INC

NYSE:MANE

MANE Rankings

MANE Latest News

MANE Latest SEC Filings

MANE Stock Data

1.52B
15.08M